RT Journal Article
SR Electronic
A1 Hitt Nichols, Emma
T1 Dasatinib Outcomes Maintained Over 5 Years
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 55
SP 19
OP 20
DO 10.1177/1559897715570603
UL http://mdc.sagepub.com/content/14/55/19.abstract
AB A new analysis from the DASISION trial showed that long-term treatment with dasatinib, compared with imatinib, in patients with treatment-naïve, chronic phase myeloid leukemia improved rates of major molecular response and molecular response, but not overall survival or progression-free survival, in the patients who completed 5 years of follow-up, without new safety signals.